Status:
COMPLETED
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the pa...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The subject has completed the full dosing period in Protocol 137-150.
Exclusion
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00107107
Start Date
November 1 2002
End Date
June 1 2005
Last Update
September 23 2015
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tempe, Arizona, United States
2
Research Site
Concord, California, United States
3
Research Site
Fresno, California, United States
4
Research Site
San Diego, California, United States